Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines

Eniko Papp, Dorothy Hallberg, Gottfried E. Konecny, Daniel C. Bruhm, Vilmos Adleff, Michaël Noë, Ioannis Kagiampakis, Doreen Palsgrove, Dylan Conklin, Yasuto Kinose, James R. White, Michael F. Press, Ronny Drapkin, Hariharan Easwaran, Stephen B. Baylin, Dennis Slamon, Victor E. Velculescu, Robert B. Scharpf

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To improve our understanding of ovarian cancer, we performed genome-wide analyses of 45 ovarian cancer cell lines. Given the challenges of genomic analyses of tumors without matched normal samples, we developed approaches for detection of somatic sequence and structural changes and integrated these with epigenetic and expression alterations. Alterations not previously implicated in ovarian cancer included amplification or overexpression of ASXL1 and H3F3B, deletion or underexpression of CDC73 and TGF-beta receptor pathway members, and rearrangements of YAP1-MAML2 and IKZF2-ERBB4. Dose-response analyses to targeted therapies revealed unique molecular dependencies, including increased sensitivity of tumors with PIK3CA and PPP2R1A alterations to PI3K inhibitor GNE-493, MYC amplifications to PARP inhibitor BMN673, and SMAD3/4 alterations to MEK inhibitor MEK162. Genome-wide rearrangements provided an improved measure of sensitivity to PARP inhibition. This study provides a comprehensive and broadly accessible resource of molecular information for the development of therapeutic avenues in ovarian cancer. The overall survival of patients with late-stage ovarian cancer is dismal. To identify therapeutic opportunities, Papp et al. integrate genomic, epigenomic, and expression analyses to provide a resource of molecular abnormalities in ovarian cancer cell lines and use these to identify tumors sensitive to PARP, MEK, and PI3K inhibitors.

Original languageEnglish (US)
Pages (from-to)2617-2633
Number of pages17
JournalCell Reports
Volume25
Issue number9
DOIs
StatePublished - Nov 27 2018
Externally publishedYes

Fingerprint

Epigenomics
Ovarian Neoplasms
Tumors
Mitogen-Activated Protein Kinase Kinases
Cells
Phosphatidylinositol 3-Kinases
Cell Line
Amplification
Genes
Transforming Growth Factor beta Receptors
Genome
Neoplasms
Therapeutics
Survival

Keywords

  • cancer cell lines
  • cancer genomics
  • drug response
  • gene fusions
  • ovarian cancer
  • structural variants

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Papp, E., Hallberg, D., Konecny, G. E., Bruhm, D. C., Adleff, V., Noë, M., ... Scharpf, R. B. (2018). Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Reports, 25(9), 2617-2633. https://doi.org/10.1016/j.celrep.2018.10.096

Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. / Papp, Eniko; Hallberg, Dorothy; Konecny, Gottfried E.; Bruhm, Daniel C.; Adleff, Vilmos; Noë, Michaël; Kagiampakis, Ioannis; Palsgrove, Doreen; Conklin, Dylan; Kinose, Yasuto; White, James R.; Press, Michael F.; Drapkin, Ronny; Easwaran, Hariharan; Baylin, Stephen B.; Slamon, Dennis; Velculescu, Victor E.; Scharpf, Robert B.

In: Cell Reports, Vol. 25, No. 9, 27.11.2018, p. 2617-2633.

Research output: Contribution to journalArticle

Papp, E, Hallberg, D, Konecny, GE, Bruhm, DC, Adleff, V, Noë, M, Kagiampakis, I, Palsgrove, D, Conklin, D, Kinose, Y, White, JR, Press, MF, Drapkin, R, Easwaran, H, Baylin, SB, Slamon, D, Velculescu, VE & Scharpf, RB 2018, 'Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines', Cell Reports, vol. 25, no. 9, pp. 2617-2633. https://doi.org/10.1016/j.celrep.2018.10.096
Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, Noë M et al. Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Reports. 2018 Nov 27;25(9):2617-2633. https://doi.org/10.1016/j.celrep.2018.10.096
Papp, Eniko ; Hallberg, Dorothy ; Konecny, Gottfried E. ; Bruhm, Daniel C. ; Adleff, Vilmos ; Noë, Michaël ; Kagiampakis, Ioannis ; Palsgrove, Doreen ; Conklin, Dylan ; Kinose, Yasuto ; White, James R. ; Press, Michael F. ; Drapkin, Ronny ; Easwaran, Hariharan ; Baylin, Stephen B. ; Slamon, Dennis ; Velculescu, Victor E. ; Scharpf, Robert B. / Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. In: Cell Reports. 2018 ; Vol. 25, No. 9. pp. 2617-2633.
@article{b618e86289d640f2a643239a56a674d1,
title = "Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines",
abstract = "To improve our understanding of ovarian cancer, we performed genome-wide analyses of 45 ovarian cancer cell lines. Given the challenges of genomic analyses of tumors without matched normal samples, we developed approaches for detection of somatic sequence and structural changes and integrated these with epigenetic and expression alterations. Alterations not previously implicated in ovarian cancer included amplification or overexpression of ASXL1 and H3F3B, deletion or underexpression of CDC73 and TGF-beta receptor pathway members, and rearrangements of YAP1-MAML2 and IKZF2-ERBB4. Dose-response analyses to targeted therapies revealed unique molecular dependencies, including increased sensitivity of tumors with PIK3CA and PPP2R1A alterations to PI3K inhibitor GNE-493, MYC amplifications to PARP inhibitor BMN673, and SMAD3/4 alterations to MEK inhibitor MEK162. Genome-wide rearrangements provided an improved measure of sensitivity to PARP inhibition. This study provides a comprehensive and broadly accessible resource of molecular information for the development of therapeutic avenues in ovarian cancer. The overall survival of patients with late-stage ovarian cancer is dismal. To identify therapeutic opportunities, Papp et al. integrate genomic, epigenomic, and expression analyses to provide a resource of molecular abnormalities in ovarian cancer cell lines and use these to identify tumors sensitive to PARP, MEK, and PI3K inhibitors.",
keywords = "cancer cell lines, cancer genomics, drug response, gene fusions, ovarian cancer, structural variants",
author = "Eniko Papp and Dorothy Hallberg and Konecny, {Gottfried E.} and Bruhm, {Daniel C.} and Vilmos Adleff and Micha{\"e}l No{\"e} and Ioannis Kagiampakis and Doreen Palsgrove and Dylan Conklin and Yasuto Kinose and White, {James R.} and Press, {Michael F.} and Ronny Drapkin and Hariharan Easwaran and Baylin, {Stephen B.} and Dennis Slamon and Velculescu, {Victor E.} and Scharpf, {Robert B.}",
year = "2018",
month = "11",
day = "27",
doi = "10.1016/j.celrep.2018.10.096",
language = "English (US)",
volume = "25",
pages = "2617--2633",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "9",

}

TY - JOUR

T1 - Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines

AU - Papp, Eniko

AU - Hallberg, Dorothy

AU - Konecny, Gottfried E.

AU - Bruhm, Daniel C.

AU - Adleff, Vilmos

AU - Noë, Michaël

AU - Kagiampakis, Ioannis

AU - Palsgrove, Doreen

AU - Conklin, Dylan

AU - Kinose, Yasuto

AU - White, James R.

AU - Press, Michael F.

AU - Drapkin, Ronny

AU - Easwaran, Hariharan

AU - Baylin, Stephen B.

AU - Slamon, Dennis

AU - Velculescu, Victor E.

AU - Scharpf, Robert B.

PY - 2018/11/27

Y1 - 2018/11/27

N2 - To improve our understanding of ovarian cancer, we performed genome-wide analyses of 45 ovarian cancer cell lines. Given the challenges of genomic analyses of tumors without matched normal samples, we developed approaches for detection of somatic sequence and structural changes and integrated these with epigenetic and expression alterations. Alterations not previously implicated in ovarian cancer included amplification or overexpression of ASXL1 and H3F3B, deletion or underexpression of CDC73 and TGF-beta receptor pathway members, and rearrangements of YAP1-MAML2 and IKZF2-ERBB4. Dose-response analyses to targeted therapies revealed unique molecular dependencies, including increased sensitivity of tumors with PIK3CA and PPP2R1A alterations to PI3K inhibitor GNE-493, MYC amplifications to PARP inhibitor BMN673, and SMAD3/4 alterations to MEK inhibitor MEK162. Genome-wide rearrangements provided an improved measure of sensitivity to PARP inhibition. This study provides a comprehensive and broadly accessible resource of molecular information for the development of therapeutic avenues in ovarian cancer. The overall survival of patients with late-stage ovarian cancer is dismal. To identify therapeutic opportunities, Papp et al. integrate genomic, epigenomic, and expression analyses to provide a resource of molecular abnormalities in ovarian cancer cell lines and use these to identify tumors sensitive to PARP, MEK, and PI3K inhibitors.

AB - To improve our understanding of ovarian cancer, we performed genome-wide analyses of 45 ovarian cancer cell lines. Given the challenges of genomic analyses of tumors without matched normal samples, we developed approaches for detection of somatic sequence and structural changes and integrated these with epigenetic and expression alterations. Alterations not previously implicated in ovarian cancer included amplification or overexpression of ASXL1 and H3F3B, deletion or underexpression of CDC73 and TGF-beta receptor pathway members, and rearrangements of YAP1-MAML2 and IKZF2-ERBB4. Dose-response analyses to targeted therapies revealed unique molecular dependencies, including increased sensitivity of tumors with PIK3CA and PPP2R1A alterations to PI3K inhibitor GNE-493, MYC amplifications to PARP inhibitor BMN673, and SMAD3/4 alterations to MEK inhibitor MEK162. Genome-wide rearrangements provided an improved measure of sensitivity to PARP inhibition. This study provides a comprehensive and broadly accessible resource of molecular information for the development of therapeutic avenues in ovarian cancer. The overall survival of patients with late-stage ovarian cancer is dismal. To identify therapeutic opportunities, Papp et al. integrate genomic, epigenomic, and expression analyses to provide a resource of molecular abnormalities in ovarian cancer cell lines and use these to identify tumors sensitive to PARP, MEK, and PI3K inhibitors.

KW - cancer cell lines

KW - cancer genomics

KW - drug response

KW - gene fusions

KW - ovarian cancer

KW - structural variants

UR - http://www.scopus.com/inward/record.url?scp=85056729935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056729935&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2018.10.096

DO - 10.1016/j.celrep.2018.10.096

M3 - Article

C2 - 30485824

AN - SCOPUS:85056729935

VL - 25

SP - 2617

EP - 2633

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 9

ER -